Summary
In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss their second episode in the "Best of 2024" series and review the highlights from the 2024 ESMO Congress. They discuss the final analysis of CheckMate 067, long-term data from KEYNOTE 006, DMFS from NADINA, and the KEYMAKER U02 Substudy 02C. The conversation also covers results from CheckMate 76K and KEYNOTE 716, as well as an exploratory analysis from KEYNOTE 054.
Keywords
ESMO 2024, melanoma, CheckMate 067, KEYNOTE 006, NADINA, KEYMAKER U02, CheckMate 76K, KEYNOTE 716, KEYNOTE 054, immunotherapy
Takeaways
The final analysis of CheckMate 067 shows sustained overall survival benefit and demonstrates cure is possible.
Melanoma-specific survival is becoming a critical endpoint in trials.
Long-term data from KEYNOTE 006 confirms durable benefit of pembrolizumab.
The NADINA study presents sustained event-free survival & DMFS benefits.
KEYMAKER U02 highlights the potential of neoadjuvant platforms.
CheckMate 76K and KEYNOTE 716 show consistent results in adjuvant settings.
The importance of staffing clinical trials for long-term follow-up is emphasized.
New endpoints like PRFS2 are being explored in studies.
Chapters
00:00 Introduction and Holiday Reflections
02:46 Key Presentations from ESMO 2024
03:44 CheckMate 067 Final, 10-Year Analysis
07:38 KEYNOTE 006: 10-Year Data
12:34 NADINA DMFS
16:25 KEYMAKER U02: Substudy 02C (Umbrella Neoadjuvant Arms 4, 5, 6)
21:07 CheckMate 76K & KEYNOTE 716
25:03 KEYNOTE 054: 7 Year Follow-up